Improving Breast Cancer Treatment
News Jan 05, 2016
The results suggest that the method might lead to more optimal treatment of individual patients.
Measuring the growth factor HER2 (human epidermal growth factor receptor type 2) is an important tool for deciding correct treatment in breast cancer. Treatments targeting HER2 are expensive but save the lives of many women. Targeted treatments have no effect if the metastases do not express HER2. The current diagnosis of elevated HER2 expression in metastatic cancer is based on examination of tissue samples obtained by surgery or needle biopsies from the liver, bones and other organs.
The aim of the current study was to develop a simpler and non-invasive technique, based on whole-body PET/CT imaging, and compare the results of image analysis to the invasive measurements in the same patients. The study included 16 women with on-going treatment of metastatic breast cancer. Twelve had been diagnosed with a HER2-positive primary tumor and four were HER2-negative. All patients were scanned using combined PET/CT and a novel tracer molecule, ABY-025 Affibody, labeled with the short-lived radioactive isotope gallium-68.
The results showed that the amount of HER2-expression in the metastases was accurately measured with the new method. In addition, the amount of HER2-expression in the metastases was frequently found to be different from the primary tumor, leading to a change in therapy in several patients.
The new method might substitute invasive tissue sampling in the near future. Our study resulted in two patients starting therapy and one patient ending therapy with HER2-targeting drugs says Jens Sörensen, PET-reseacher and adjunct professor at the Institution of Surgical Sciences, Uppsala University.
The research group now plans a larger study with more participating hospitals to confirm the results with the intention of making the new method more widely available to patients.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.